{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:18Z","timestamp":1789609098754,"version":"build-2803163510"},"reference-count":66,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with cutaneous T\u2010cell lymphoma with progressive disease typically undergo a series of skin\u2010directed and systemic therapy regimens during cycles of response and relapse. Extracorporeal photopheresis (ECP) is an effective and safe systemic treatment option, often reserved for later stages of disease and typically employed after failure of several other therapies. ECP has benefits in response rate, time to next treatment, and tolerability that may support its use earlier in the treatment cycle for advancing\/progressing disease.<\/jats:p>","DOI":"10.1002\/hon.3229","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:39:57Z","timestamp":1700210397000},"page":"809-816","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early intervention of extracorporeal photopheresis for advancing\/progressing cutaneous T\u2010cell lymphoma"],"prefix":"10.1002","volume":"41","author":[{"given":"Daniel","family":"Aires","sequence":"first","affiliation":[{"name":"Dermatology  Oakland California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8578-1226","authenticated-orcid":false,"given":"Sunil","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"University of Kansas Cancer Center and the University of Kansas Medical Center  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102921"},{"key":"e_1_2_13_3_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Primary Cutaneous Lymphomas.\u00a9National Comprehensive Cancer Center Network Inc. 2023. All rights reserved. To View the Most Recent and Complete Version of the Guideline Go Online to NCCN.Org. NCCN Makes No Warranties of Any Kind Whatsoever Regarding Their Content Use or Application and Disclaims Any Responsibility for Their Application or Use in Any WayV.1.2023.NCCN National Comprehensive Cancer Network\u00ae(NCCN\u00ae);2023."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00765"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.01.02"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17117"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201011\u2010881268"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.12.03"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.06.006"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci200524826"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.11.006"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201012\u20100604"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201005\u2010154609"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.7142"},{"issue":"1","key":"e_1_2_13_18_1","first-page":"190","article-title":"Health\u2010related quality of life and economic implications of cutaneous T\u2010cell lymphoma","volume":"182","author":"Rosenberg AR","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.45"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00260"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201007\u2010588236"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1587144"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12254"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.033"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2013.07.009"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11127"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12690"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.3969"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12311"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100781.2012.00689.x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.010"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14366"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.12341"},{"issue":"11","key":"e_1_2_13_34_1","first-page":"3586","article-title":"Methotrexate in the treatment of mycosis fungoides \u2010 a multicenter observational study in 79 patients","volume":"22","author":"Olek\u2010Hrab K","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30379\u20106"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01056"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s61308"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000765"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010018\u20103275\u2010z"},{"issue":"2","key":"e_1_2_13_40_1","first-page":"148","article-title":"Imiquimod in mycosis fungoides","volume":"18","author":"Martinez\u2010Gonzalez MC","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"5","key":"e_1_2_13_41_1","first-page":"466","article-title":"Safe and efficacious use of intralesional steroids for the treatment of focally resistant mycosis fungoides","volume":"14","author":"Liu DY","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.12.002"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.25.8301"},{"key":"e_1_2_13_44_1","volume-title":"(bexaroten) Capsules [prescribing Information]","author":"Targretin","year":"2020"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.008"},{"key":"e_1_2_13_46_1","volume-title":"(romidepsin) for Injection [package Insert]","author":"Istodax","year":"2018"},{"key":"e_1_2_13_47_1","volume-title":"(vorinostat) Capsules for Oral Use. [package Insert]","author":"Zolinza X","year":"2020"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00645"},{"key":"e_1_2_13_49_1","volume-title":"(mogamulizumab\u2010kpkc) Injection [package Insert]","author":"Poteligeo","year":"2021"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596"},{"key":"e_1_2_13_51_1","volume-title":"(brentuximab Vedotin) [prescribing Information]","author":"Adcetris X","year":"2019"},{"key":"e_1_2_13_52_1","volume-title":"International Conference on Malignant Lymphoma","author":"Horwitz SM","year":"2019"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00236"},{"issue":"6","key":"e_1_2_13_54_1","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen K","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.129.6.747"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2017.05.001"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105510"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13243"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.007"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010020\u201001197\u20103"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.3241"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2719"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00349"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1873530"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1412064"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466026"},{"issue":"10","key":"e_1_2_13_67_1","first-page":"1212","article-title":"75% Complete response and 15% partial response to extracorporeal photopheresis combined with other therapies in resistant early stage cutaneous T\u2010cell lymphoma","volume":"15","author":"Seremet S","year":"2016","journal-title":"J Drugs Dermatol"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T13:21:47Z","timestamp":1703510507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/hon.3229"],"URL":"https:\/\/doi.org\/10.1002\/hon.3229","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"2022-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}